Type 2 diabetes is a progressive condition in which the body becomes resistant to the normal effects of insulin and/or gradually loses the capacity to produce enough insulin in the pancreas. We do not know what causes type 2 diabetes. Type 2 diabetes is associated with modifiable lifestyle risk factors. Type 2 diabetes also has strong genetic and family related risk factors.
The dramatic increase in the prevalence, progressive nature and diagnosis of type 2 diabetes is the main driver of this rapid growth rate. The rise in disease-related comorbidities has also fuelled a more aggressive approach to treatment, including the use of multiple-drug therapies.
Get Exclusive Sample Report @ https://dataintelo.com/request-sample/?reportId=7092
The Americas dominated the global type 1 diabetes drug market and accounted for close to 50% of the global type 1 diabetes market size. The US was the largest revenue contributor to the diabetes drug market in this region because of the growing prevalence of the disease and rise in obesity. The accessibility to therapies by reimbursement programs is further expected to drive the growth of the diabetes drug market size in the Americas.
